Trials / Completed
CompletedNCT00861068
A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the trial is to investigate the analgesic efficacy of SPM 927 in subjects with moderate to severe neuropathic pain due to Postherpetic Neuralgia (PHN)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPM927/Lacosamide | SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks |
| OTHER | Placebo | Placebo tablets two times a day for 10 weeks |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2002-12-01
- Completion
- 2003-01-01
- First posted
- 2009-03-13
- Last updated
- 2024-04-19
Source: ClinicalTrials.gov record NCT00861068. Inclusion in this directory is not an endorsement.